ArticleClinical and translational radiation oncology2027
MR-guided ultra-hypofractionated radiotherapy for early-stage glottic cancer: A phase I feasibility study.
Article in Clinical and translational radiation oncology, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ultra-hypofractionation for early-stage glottic cancer reduces the number of hospital visits, but requires precise delivery to minimize the risk of radiation-induced toxicity. Magnetic Resonance (MR)-guided radiotherapy is a delivery technique that enables visualization of the tumor and laryngeal cartilages at each treatment session. In addition, motion management provides confidence that radiation is delivered precisely to the tumor while minimizing dose to the laryngeal cartilages. This study evaluates the feasibility and safety of an MR-guided ultra-hypofractionated treatment for early-stage glottic cancer. Study design: This is a prospective, single-center phase I feasibility study conducted at the University Medical Center (UMC) Utrecht. Twenty patients with cT1-2N0M0 squamous cell carcinoma of the glottic larynx and an indication for definitive radiotherapy will be enrolled. Active smokers and patients who do not meet the dose criteria will be excluded from the study. Patients receive 5 × 8.5 Gy, divided over three weeks (2 fractions per week). The GTV-PTV margin is 2 mm anterior-posterior, 2 mm left-right, and 4 mm cranio-caudal. The treatment is delivered on a 1.5 T MR-Linac (Elekta Unity), using online plan adaptation and motion management. Endpoints: The primary endpoints are technical feasibility and safety. MR-guided ultra-hypofractionated radiotherapy will be considered feasible if at least 80% of the patients (16/20 patients) successfully complete all five treatment fractions on the MR-Linac. The treatment is considered safe if a maximum of 10% of the patients (2/20 patients) experience a grade 3 disease-free late toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.